Volume 1, # 5 - September, 1995
Table of Contents
|
| STATE-OF-THE-ART MANAGEMENT OF CANCER |
| MALIGNANT MELANOMA |
| Etiology and Risk Factors |
117 |
| Pathogenesis, Classification, Staging and Prognosis |
118 |
| Epidemiology |
119 |
| Diagnosis |
122 |
| Current Disease Management Approaches |
123 |
| Surgery |
124 |
| Chemotherapy |
125 |
| Dacarbazine |
125 |
| Fotemustine |
125 |
| Vindesine |
125 |
| Interferon-alpha 2b |
126 |
| Interferon-alpha 2a |
126 |
| Sequential Chemoimmunotherapy |
126 |
| MEETING COVERAGE |
19TH INTERNATIONAL CONGRESS OF CHEMOTHERAPY
Montreal, Quebec, Canada - July 16-21, 1995 |
| New Treatment Approaches for Infections In Neutropenic Patients |
127 |
| Piperacillin/Tazobactam |
127 |
| Recombinant Granulocyte-Colony Stimulating Factor Combination Therapy |
128 |
| Meropenem |
128 |
| Pefloxacin with Teicoplanin |
128 |
| Ciprofloxacin |
128 |
| Fluconazole |
128 |
| MECHANISMS IN MALIGNANCY |
| DRUG RESISTANCE IN CANCER - PART III |
| Novel Agents in Development to Overcoming P-Glycoprotein-Mediated Resistance |
129 |
| Novel Drugs Being Evaluated in P-gp MDR |
129 |
| Byk Gulden |
129 |
| Cell Therapeutics |
129 |
| CytRx |
129 |
| Knoll Pharmaceuticals |
129 |
| Vertex Pharmaceuticals |
130 |
| Xenova |
130 |
| Oligonucleotide-based agents/ribozymes |
130 |
| Other agents in development |
131 |
| Drug Delivery Methodologies Used to Reverse P-gp MDR |
132 |
| Aronex |
132 |
| Combination of MDR Modulators in Cancer Therapy |
132 |
| Monoclonal Antibodies |
133 |
| Imgenex |
133 |
| Overcoming Other Types of MDR |
133 |
| Overcoming Resistance to Topoisomerase II Poisons |
133 |
| Overcoming Resistance to Free Radical-Mediated Drug Cytotoxicity |
133 |
| Overcoming Resistance to Alkylating Agents and Platinum Compounds |
133 |
| Terrapin Technologies |
134 |
| Institute Pasteur |
134 |
| Overcoming Resistance to Antimetabolites |
134 |
| Sparta Pharmaceuticals |
135 |
| Reversal of Apoptosis-Mediated Chemoresistance |
136 |
